Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Ticagrelor

Ticagrelor

P2Y12 inhibitor (cyclopentyl-triazolo-pyrimidine β€” reversible binding)

DAPTACSAdult

Indication

ACS DAPT β€’ Post-MI long-term selected (region/label)

At a glance

INDICATIONS (CORE USE)

ACS with aspirin β€” **dyspnea**, **bradycardia**; **BID**; CYP3A4 interactions.

ADULT DOSE (STANDARD)

Loading **180 mg** then **90 mg BID** Γ— up to 12 mo ACS; then often **60 mg BID** continuation per label

MAX DOSE

90 mg BID acute phase per label

Route

PO

PEDIATRIC DOSE

Not established

Do not miss

Must-not-miss safety points

Major warning

- **Dyspnea** β€” common; HF vs drug - **Bradyarrhythmia** post-ACS - Bleeding on DAPT

Indications

USE IF: ACS DAPT when guideline selects ticagrelor. AVOID IF: Active bleeding, strong CYP3A4 contraindications per label, history of ICH (context).

Primary

  • ACS (with aspirin) per cardiology pathway

Secondary

  • Post-MI extended therapy in some regions

Dosing

STANDARD (ADULT PO)

90 mg BID with maintenance aspirin after 180 mg load (ACS)

ADULT DOSE

Transition to 60 mg BID after 12 months ACS per label; verify local guideline.

PEDIATRIC DOSE

N/A

MAX DOSE

90 mg BID

Practical Note

Missed dose β€” do not double next dose per label.

Warnings

Clinical warnings

  • **Major bleeding** (GI, ICH, post-procedural) β€” higher with **DAPT**, triple therapy, renal failure, age β€” counsel early symptoms
  • **DAPT after PCI/ACS:** duration is **indication- and stent-specific** β€” **do NOT stop prematurely** without **cardiology** (premature stop β†’ **stent thrombosis**, MI, death)
  • Elective surgery after recent stent β†’ **perioperative plan** with cardiology + surgery β€” **do not** assume β€œhold all antiplatelets” is safe
  • **Ticagrelor:** **dyspnea** and **bradycardia** β€” distinguish from ACS decompensation; **CYP3A4** drug interactions
  • Dyspnea
  • bradycardia
  • ventricular pauses

Adverse effects

  • Dyspnea
  • bleeding
  • bradycardia
  • hyperuricemia

Contraindications

  • **Active major bleeding** β€” hold until controlled unless embedded in explicit procedural plan
  • **Active bleeding** with need for urgent surgery β€” coordinate with cardiology if recent stent
  • Active bleeding
  • severe hepatic impairment
  • strong CYP3A4 inhibitors per label

Drug interactions

  • **Anticoagulant or NSAID added on DAPT** β†’ **bleeding risk ↑** β†’ **reassess duration** (triple therapy only when justified)
  • **Strong CYP3A4 inhibitor/inducer (ticagrelor)** or **CYP2C19 issue (clopidogrel)** β†’ **avoid or switch** per cardiology/pharmacy β€” do not ignore
  • Strong CYP3A4 inhibitors/inducers
  • high-dose simvastatin/lovastatin

Special populations

Pediatrics

Not established

Pregnancy

Avoid pregnancy

Lactation

β€” risk/benefit

Renal impairment

No CrCl adjustment typical β€” monitor bleed on combination therapy **Renal:** no routine dose adjustment; **bleeding risk** may be higher in advanced CKD on combination therapy β€” clinical vigilance

Hepatic impairment

Severe hepatic impairment β€” contraindicated

Elderly

Bleed risk

Administration

PO with or without food; BID adherence critical

Monitoring

  • Monitor: - **Coronary stent / recent PCI** β†’ **do NOT stop DAPT early** without **cardiology** β€” duration **ACS vs stable CAD** differs - **New dyspnea** β†’ **HF vs drug** β€” cardiology if limiting - **Bradyarrhythmia / pauses** early post-ACS β†’ monitor HR - **DAPT** β†’ **no elective interruption** without cardiology; **procedure** β†’ explicit review - Heart rate early post-ACS - bleeding
  • Recheck: - **Planned invasive procedure in 48–72h** β†’ **pre-op antiplatelet review** with cardiology + surgery β€” document **bleed vs stent thrombosis** - **Strong CYP3A4 drug added** β†’ **avoid or switch** per label β€” reassess before surgery - New or worsening **bleeding**, unexplained **Hb drop**, or planned invasive procedure within **48–72h** β†’ reassess antiplatelet plan with cardiology/surgery when on DAPT - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding or unexplained Hb drop** β†’ **hold strategy** is team-based β€” do not stop all agents without plan

Overdose / toxicity

Clinical Picture

**A) Therapeutic complication:** **bleeding** on DAPT/triple therapy or peri-procedure β€” **no** classic β€œsupratherapeutic serum level” syndrome for oral P2Y12. **B) Massive oral overdose:** management is **supportive + bleeding care**; **no** specific antidote β€” **not** salicylate-style toxicology unless co-ingestion.

Immediate Actions

**A:** Stop P2Y12 (and often aspirin in DAPT) per **cardiology + surgery** plan β†’ mechanical hemostasis; transfuse as indicated β€” **stent timing** if interruption considered. **B:** Charcoal if very early massive ingestion + protected airway; otherwise **observe + bleed surveillance**

Antidote

No specific antidote; treat complications (supportive care, platelets / hemostasis per protocol, anaphylaxis β†’ epinephrine per ACLS)

Decontamination

**B:** Charcoal only if massive ingestion within narrow window; **A:** N/A maintenance therapy

Escalation

**ICH** or unstoppable surgical bleed β†’ **ICU**; platelet transfusion **does not fully reverse** P2Y12 β€” **procedural/heme judgment**

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**BID** β€” adherence. β†’ Dyspnea workup. β†’ CYP3A4 screen.

Clinical pearls

ASA maintenance dose often limited with ticagrelor per label β€” follow local. *Antiplatelet (all agents):* **Primary vs secondary (aspirin):** primary **not routine**; secondary **strong** when guideline-supported. **DAPT:** **do not stop early** post-stent without expert; duration **ACS vs stable CAD**; procedures need **explicit review**. **Bleeding-first:** GI/ICH/peri-op; **duplicate/hidden aspirin** on med rec. **Aspirin toxicity** (salicylate) is a **separate pathway** from antiplatelet bleed.

Antiplatelet safety

  • Dyspnea
  • HR monitoring
  • CYP3A4 meds

Pharmacokinetics

Direct-acting; shorter offset than thienopyridines for elective surgery planning.

Mechanism of action

Reversible P2Y12 antagonist.

Common brand names

Saudi Arabia

Brilique, Ticagrelor

Global

Brilinta, (placeholder β€” verify local product)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • DAPT duration and perioperative management follow **ESC/AHA/ACC** and local cardiology consensus β€” not one-size rules.
  • Primary prevention aspirin thresholds differ by guideline and age β€” verify regional primary-care policy.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol

Do not miss

  • Document antiplatelet indication (primary vs secondary prevention vs stent DAPT)
  • Med reconciliation: OTC aspirin, NSAIDs, fish oil, anticoagulants
  • **Dyspnea:** Can mimic HF β€” do not ignore; cardiology review if new/limiting.
  • **Bradyarrhythmia:** Especially early post-ACS β€” monitor; pauses reported.
  • **DAPT interruption:** Stented patients need **cardiology-led** plan β€” **stent thrombosis** if stopped ad hoc.
  • **CYP3A4:** Strong inhibitors/inducers β†’ **avoid or switch** per label β€” reassess exposure before procedures.
  • Attributing ACS dyspnea to HF alone β€” ticagrelor on board.
  • **DAPT (factory rules):**
  • **Do NOT stop early** after coronary stent unless **cardiology/expert**-directed β€” premature stop β†’ **stent thrombosis**.
  • **Duration** depends on **ACS vs stable CAD/PCI** context β€” not one schedule for all.
  • **Planned procedure** β†’ **explicit antiplatelet review** with cardiology + surgery β€” document **bleed vs thrombosis** tradeoff.
  • Dyspnea
  • HR monitoring
  • CYP3A4 meds